New pill targets brain inflammation in Parkinson's – first human tests begin

NCT ID NCT06997484

Recruiting now Disease control Sponsor: Highlightll Pharmaceutical (USA) LLC Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests an experimental oral drug called HL-400 in 86 healthy volunteers. The drug aims to block a protein (NLRP3) linked to inflammation, which may play a role in Parkinson's disease. The study focuses on safety, tolerability, and how the drug moves through the body, not yet on treating Parkinson's symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HL-400 (an oral NLRP3 inhibitor)
What this could lead to: If successful, this could pave the way for a new treatment that slows Parkinson's disease by targeting inflammation in the brain.
What could go wrong: This is a very early Phase 1 trial in healthy people, not Parkinson's patients. It only tests safety and dosing, not whether the drug works for the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON DISEASE

Contacts and locations

Locations

Pharmaron CPC, Inc.
RECRUITING

Baltimore, Maryland, 21201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.